Revenue
2015
2016
2017
2018
2019
2020
2021
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $2.27T | $2.02T | $1.92T | $1.83T | $1.80T | $1.68T | $1.64T |
| Research & development | $592.0M | $627.0M | $1.79B | $2.58B | $2.31B | $1.56B | $2.81B | — | — | — | — |
| Operating expenses | $1.04T | $1.02T | $909.70B | $961.33B | $901.29B | $842.47B | $801.89B | $754.31B | — | — | — |
| Operating income | — | — | — | — | $1.07T | $693.88B | $793.54B | $761.74B | $716.32B | $584.45B | $525.54B |
| EBITDAderived | — | — | — | — | $1.20T | $803.30B | $899.63B | $841.02B | $794.14B | $649.81B | $579.15B |
| Net income | $1.02T | $852.96B | $579.43B | $792.28B | −$842.47B | −$547.61B | −$619.09B | $595.33B | $562.80B | $476.07B | $448.47B |
| Basic EPSper diluted share | CLP 5.42 | CLP 4.53 | CLP 3.08 | CLP 4.20 | CLP 4.47 | CLP 2.91 | CLP 3.29 | CLP 3.16 | CLP 2.99 | CLP 2.53 | CLP 2,380.00 |
| Diluted EPSper diluted share | CLP 5.42 | CLP 4.53 | CLP 3.08 | CLP 4.20 | CLP 4.47 | CLP 2.91 | CLP 3.29 | CLP 3.16 | CLP 2.99 | CLP 2.53 | CLP 2,380.00 |